Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2016, Article ID 2138259, 9 pages
Research Article

Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy

1University of Arkansas for Medical Sciences, Little Rock, AR, USA
2Duke University, Durham, NC, USA
3University of Washington, Seattle, WA, USA
4Memorial Sloan-Kettering Cancer Center, New York, NY, USA
5University of California, San Francisco, San Francisco, CA, USA
6Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, USA
7AIDS Malignancy Consortium, New York, NY, USA
8Johns Hopkins University, Baltimore, MD, USA
9University of California, Los Angeles, Los Angeles, CA, USA

Received 6 June 2016; Revised 27 September 2016; Accepted 11 October 2016

Academic Editor: Yun-Ling Zheng

Copyright © 2016 Jeannette Y. Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at least one claim with a diagnostic code for HIV and at least one filled prescription for an antiretroviral medication between January 1, 2006, and September 30, 2012, were obtained from the LifeLink® Health Plan Claims Database. The expected number of cancer cases in the general population for each gender-age group (<30, 30–39, 40–49, 50–59, and >60 years) was estimated using incidence rates from the Surveillance Epidemiology and End Results (SEER) program. Standardized incidence ratios (SIRs) were estimated using their 95% confidence intervals (CIs). Compared to the general population, incidence rates for HIV-infected adults were elevated (SIR, 95% CI) for Kaposi sarcoma (46.08; 38.74–48.94), non-Hodgkin lymphoma (4.22; 3.63–4.45), Hodgkin lymphoma (9.83; 7.45–10.84), and anal cancer (30.54; 25.62–32.46) and lower for colorectal cancer (0.69; 0.52–0.76), lung cancer (0.70; 0.54, 0.77), and prostate cancer (0.54; 0.45–0.58). Commercially insured, treated HIV-infected adults had elevated rates for infection-related cancers, but not for common non-AIDS defining cancers.